Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3493-3500

  Morgan, Matthew D ^a   Turnbull, Jennifer ^b   Selamet, Umut ^c   Kaur Hayer, Manvir ^d   Nightingale, Peter ^d   Ferro, Charles J ^d   Savage, Caroline O S ^a   Harper, Lorraine ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b STOKE MANDEVILLE HOSPITAL   (United Kingdom)

^c ST VINCENT S MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DIALYSIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REMISSION; STROKE; TRANSIENT ISCHEMIC ATTACK;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 70350534599     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24957     Document Type: Article

References (34)

1. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-784 (Pubitemid 36396745)
2. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-1010 (Pubitemid 351956664)
3. Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001;60:1156-1157
4. Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008;35:398-406.
5. Wallberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantapaa-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol 2008;37:1-5.
6. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1780-1784
7. Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ, et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003;62:162-167 (Pubitemid 36135393)
8. De Leeuw K, Kallenberg C, Bijl M. Accelerated atherosclerosis in patients with systemic autoimmune diseases. Ann N Y Acad Sci 2005;1051:362-371 (Pubitemid 41362766)
9. Sangle SR, Davies RJ, Mora M, Baron MA, Hughes GR, D'Cruz DP. Ankle-brachial pressure index: a simple tool for assessing cardiovascular risk in patients with systemic vasculitis. Rheumatology (Oxford) 2008;47:1058-1060 (Pubitemid 351865933)
10. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192 (Pubitemid 24065492)
11. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-380 (Pubitemid 27114101)
12. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 1977;63:200-207
13. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-1510 (Pubitemid 26035533)
14. Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 2005;17:234-241
15. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-346
16. Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 2008;102:1668-1673
17. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293-303. (Pubitemid 46053442)
18. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005;98:97-111. (Pubitemid 40277566)
19. De Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005;64:753-759 (Pubitemid 40559304)
20. Pagnoux C, Chironi G, Simon A, Guillevin L. Atherosclerosis in ANCA-associated vasculitides. Ann N Y Acad Sci 2007;1107:11-21.
21. Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007;192:391-395 (Pubitemid 46726319)
22. Hafstrom I, Rohani M, Deneberg S, Wornert M, Jogestrand T, Frostegard J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis - a randomized study. J Rheumatol 2007;34:1810-1816 (Pubitemid 350067638)
23. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47:72-75 (Pubitemid 350286266)
24. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-845 (Pubitemid 37026494)
25. Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109:1718-1723 (Pubitemid 38500672)
26. Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, et al. Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006;80:275-281 (Pubitemid 44313905)
27. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006;24:309-312 (Pubitemid 44151152)
28. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 2007;17:385-390 (Pubitemid 47593486)
29. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008;117:2662-2669
30. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-3957
31. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-2406 (Pubitemid 37542988)
32. Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852-858 (Pubitemid 47268750)
33. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005;32:2095-2101 (Pubitemid 41587851)
34. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007;46:1560-1565